This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know?

Cormorant Asset Management increased its MoonLake Immunotherapeutics position by 2,361,260 shares in Q4, an estimated $27.86 million trade based on average quarterly prices. The move represents a notable institutional accumulation in the biotech name but is unlikely on its own to materially move the stock; monitor follow-through in filings, price, and volume.

Analysis

Cormorant Asset Management increased its MoonLake Immunotherapeutics position by 2,361,260 shares in Q4, an estimated $27.86 million trade based on average quarterly prices. The move represents a notable institutional accumulation in the biotech name but is unlikely on its own to materially move the stock; monitor follow-through in filings, price, and volume.